NeuroMedix pre-clinical study on Minozac finds wide safety window

By Lisa Kerner

Charlotte, N.C., Sept. 12 - NeuroMedix Inc. said the maximum tolerated dose found in an animal study of its lead candidate Minozac for the treatment of Alzheimer's disease was well above the levels that would be used for treatment.

The studies defined the MTD of the compound based on oral dosing to be in excess of 40 times the therapeutic dose used in a mouse model of Alzheimer's disease.

NeuroMedix said the drug, which reduces brain inflammation to protect neuron cells, has no obvious side-effects that might limit its therapeutic use in human patients.

Longer-term 28-day repeat dose studies and additional safety pharmacology studies are planned, according to the Toronto-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.